Novo Nordisk’s CagriSema tops Wegovy in new diabetes trial — 14.2% weight loss at top dose
Novo Nordisk said its experimental CagriSema injection led to 14.2% weight loss over 68 weeks in adults with type 2 diabetes, outperforming Wegovy’s 10.2%. HbA1c fell by 1.91 percentage points with CagriSema, compared to 1.76 with semaglutide alone. The company plans to seek regulatory approval for CagriSema in type 2 diabetes. Most side effects were gastrointestinal and mild to moderate.
